MNOV - MediciNova, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
La Jolla,
United States
Type: Equity
MNOV price evolution
MNOV
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $51 | $51.51 | $52.88 | $55.26 |
| Short term investments | ||||
| Net receivables | $1 | |||
| Inventory | ||||
| Total current assets | $51.17 | $53 | $53.52 | $56.03 |
| Long term investments | ||||
| Property, plant & equipment | $0.62 | $0.67 | $0.72 | $0.62 |
| Goodwill & intangible assets | $9.6 | $9.6 | $9.6 | $9.6 |
| Total noncurrent assets | $15.1 | $15.14 | $15.2 | $15.1 |
| Total investments | ||||
| Total assets | $66.27 | $68.14 | $68.72 | $71.13 |
| Current liabilities | ||||
| Accounts payable | $1 | $0.74 | $0.55 | $0.59 |
| Deferred revenue | ||||
| Short long term debt | $0.22 | $0.21 | $0.2 | $0.14 |
| Total current liabilities | $3.28 | $2.8 | $2.82 | $2.72 |
| Long term debt | ||||
| Total noncurrent liabilities | $0.61 | $0.67 | $0.72 | $0.69 |
| Total debt | $0.22 | $0.21 | $0.2 | $0.14 |
| Total liabilities | $3.89 | $3.47 | $3.54 | $3.41 |
| Shareholders' equity | ||||
| Retained earnings | -$415.7 | -$413.64 | -$412.92 | -$410.05 |
| Other shareholder equity | -$0.12 | -$0.12 | -$0.12 | -$0.12 |
| Total shareholder equity | $62.38 | $64.67 | $65.18 | $67.73 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $51 | $18.51 | $71.43 | $60.04 |
| Short term investments | $39.98 | |||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $51.17 | $58.99 | $72.01 | $60.72 |
| Long term investments | ||||
| Property, plant & equipment | $0.62 | $0.67 | $0.88 | $0.06 |
| Goodwill & intangible assets | $9.6 | $9.6 | $9.6 | $9.6 |
| Total noncurrent assets | $15.1 | $15.17 | $15.4 | $14.7 |
| Total investments | $39.98 | |||
| Total assets | $66.27 | $74.15 | $87.41 | $75.42 |
| Current liabilities | ||||
| Accounts payable | $1 | $0.42 | $0.4 | $0.62 |
| Deferred revenue | $1.69 | |||
| Short long term debt | $0.22 | $0.16 | $0.13 | |
| Total current liabilities | $3.28 | $3.19 | $2.83 | $2.19 |
| Long term debt | ||||
| Total noncurrent liabilities | $0.61 | $0.73 | $0.9 | $1.9 |
| Total debt | $0.22 | $0.16 | $0.13 | |
| Total liabilities | $3.89 | $3.91 | $3.73 | $4.09 |
| Shareholders' equity | ||||
| Retained earnings | -$415.7 | -$407.13 | -$393.06 | -$382.93 |
| Other shareholder equity | -$0.12 | -$0.12 | -$0.1 | -$0.09 |
| Total shareholder equity | $62.38 | $70.24 | $83.68 | $71.33 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1 | |||
| Cost of revenue | ||||
| Gross Profit | $1 | |||
| Operating activities | ||||
| Research & development | $1.65 | $0.79 | $1.74 | $1.48 |
| Selling, general & administrative | $0.84 | $1.35 | $1.56 | $1.49 |
| Total operating expenses | $1.99 | $2.16 | $3.32 | $3.43 |
| Operating income | -$1.99 | -$1.16 | -$3.32 | -$3.43 |
| Income from continuing operations | ||||
| EBIT | -$2.06 | -$0.72 | -$2.87 | -$2.92 |
| Income tax expense | $0 | |||
| Interest expense | ||||
| Net income | ||||
| Net income | -$2.06 | -$0.72 | -$2.87 | -$2.92 |
| Income (for common shares) | -$2.06 | -$0.72 | -$2.87 | -$2.92 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1 | $4.04 | ||
| Cost of revenue | ||||
| Gross Profit | $1 | $4.04 | ||
| Operating activities | ||||
| Research & development | $5.66 | $9.14 | $8.54 | $7.48 |
| Selling, general & administrative | $5.24 | $5.48 | $5.72 | $6.69 |
| Total operating expenses | $10.9 | $14.63 | $14.25 | $14.18 |
| Operating income | -$9.9 | -$14.63 | -$10.22 | -$14.18 |
| Income from continuing operations | ||||
| EBIT | -$8.57 | -$14.07 | -$10.13 | -$13.86 |
| Income tax expense | $0 | $0 | $0 | -$0 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$8.57 | -$14.07 | -$10.13 | -$13.85 |
| Income (for common shares) | -$8.57 | -$14.07 | -$10.13 | -$13.85 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$2.06 | -$0.72 | -$2.87 | -$2.92 |
| Operating activities | ||||
| Depreciation | $0.05 | $0.05 | $0.05 | $0.05 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | -$0.24 | $0.22 | $0.33 | $0.4 |
| Total cash flows from operations | -$0.5 | -$1.37 | -$2.38 | -$3.18 |
| Investing activities | ||||
| Capital expenditures | $0 | -$0 | -$0.02 | |
| Investments | $39.93 | |||
| Total cash flows from investing | $0 | -$0 | -$0.02 | $39.93 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | ||||
| Effect of exchange rate | -$0.01 | $0.01 | $0.02 | $0 |
| Change in cash and equivalents | -$0.51 | -$1.37 | -$2.38 | $36.75 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$8.57 | -$14.07 | -$10.13 | -$13.85 |
| Operating activities | ||||
| Depreciation | $0.21 | $0.21 | $0.24 | $0.02 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.71 | $0.64 | $1.72 | $3.18 |
| Total cash flows from operations | -$7.43 | -$12.91 | -$9.38 | -$10.83 |
| Investing activities | ||||
| Capital expenditures | -$0.02 | -$0.01 | -$0.03 | -$0.04 |
| Investments | $39.93 | -$40 | ||
| Total cash flows from investing | $39.91 | -$40.01 | -$0.03 | -$0.04 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.01 | $20.78 | $7.11 | |
| Net borrowings | ||||
| Total cash flows from financing | $0.01 | $20.78 | $7.11 | |
| Effect of exchange rate | $0.02 | -$0.02 | $0.03 | $0 |
| Change in cash and equivalents | $32.49 | -$52.93 | $11.39 | -$3.76 |
News
Fundamentals
| Market cap | $68.66M |
|---|---|
| Enterprise value | $17.88M |
| Shares outstanding | 49.05M |
| Revenue | $1000.00K |
|---|---|
| EBITDA | -$8.35M |
| EBIT | -$8.57M |
| Net Income | -$8.57M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -8.01 |
|---|---|
| EV/Sales | 17.88 |
| EV/EBITDA | -2.14 |
| EV/EBIT | -2.09 |
| P/S ratio | 68.66 |
| P/B ratio | 1.10 |
| Book/Share | 1.27 |
| Cash/Share | 1.04 |
| EPS | -$0.17 |
|---|---|
| ROA | -12.50% |
| ROE | -13.19% |
| Debt/Equity | 0.06 |
|---|---|
| Net debt/EBITDA | 5.64 |
| Current ratio | 15.61 |
| Quick ratio | 15.61 |